Name: End-stage renal disease: CMS should assess adequacy of payment when certain oral drugs are included and ensure availability of quality monitori (en Inglés)
Price: 493.61 MXN
Availability: InStock
Author: Office, U. S. Government Accountability
ISBN: 9781974622214

Envío gratis

portada End-stage renal disease: CMS should assess adequacy of payment when certain oral drugs are included and ensure availability of quality monitori (en Inglés)

Formato

Libro Físico

Autor

U. S. Government Accountability Office

Editorial

Createspace Independent Publishing Platform

Idioma

Inglés

N° páginas

Encuadernación

Tapa Blanda

Dimensiones

28.0 x 21.6 x 0.3 cm

Peso

0.13 kg.

ISBN13

9781974622214

Categorías

Métodos de investigación

End-stage renal disease: CMS should assess adequacy of payment when certain oral drugs are included and ensure availability of quality monitori (en Inglés)

U. S. Government Accountability Office (Autor) · Createspace Independent Publishing Platform · Tapa Blanda

Libro Nuevo

$ 493.61

$ 897.48

Ahorras: $ 403.87

45% descuento

Envío normal

Origen: Estados Unidos (Costos de importación incluídos en el precio)

Se enviará desde nuestra bodega entre el Miércoles 31 de Julio y el Jueves 08 de Agosto.

Lo recibirás en cualquier lugar de México entre 1 y 3 días hábiles luego del envío.

Reseña del libro "End-stage renal disease: CMS should assess adequacy of payment when certain oral drugs are included and ensure availability of quality monitori (en Inglés)"

"FOr most individuals with end-stage renal disease (ESRD), Medicare purchases a bundle of dialysis-related services using a single payment. In 2014, the Centers for Medicare & Medicaid Services (CMS) plans to include in this bundled payment "oral-only" ESRD drugs used to treat mineral and bone disorder. Currently, Medicare generally pays for these drugs only if the beneficiary has Part D prescription drug coverage. This report (1) describes the rationales for including oral-only ESRD drugs in the bundled payment, (2) examines dialysis organizations' recent experience providing oral-only ESRD drugs and their future ability to provide these drugs, (3) examines the data sources that CMS could use to account for oral-only ESRD drugs in the bundled payment, and (4) examines CMS's ability to monitor treatment of mineral and bone disorder. GAO interviewed CMS officials, experts in mineral and bone disorder, and representatives of 4 large and 16 small dialysis organizations. GAO also reviewed ESRD payment regulations, related reports, clinical guidelines, and state pharmacy licensure requirements in 10 selected states. GAO recommends that CMS assess payment adequacy when oral-only ESRD drugs are included in the bundled payment and ensure availability of reliable data for..."